LTI Stock Overview A clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. More details
Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Aptose Biosciences Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Aptose Biosciences Historical stock prices Current Share Price CA$0.21 52 Week High CA$2.08 52 Week Low CA$0.13 Beta 0.97 1 Month Change 13.81% 3 Month Change -37.58% 1 Year Change -90.00% 3 Year Change -98.82% 5 Year Change -99.75% Change since IPO -99.69%
Recent News & Updates
Aptose Biosciences Inc. Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial Jan 10
Aptose Biosciences Inc. Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib's Unique Mechanism of Action and Synthetic Lethality on Aml Cells When Combined with Venetoclax Dec 13
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML Dec 10 Aptose Biosciences Inc. has completed a Follow-on Equity Offering in the amount of $8 million. Nov 26
Aptose Biosciences Inc. Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-Based Triplet Therapy Nov 20
New major risk - Financial position Nov 17 See more updates
Aptose Biosciences Inc. Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial Jan 10
Aptose Biosciences Inc. Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib's Unique Mechanism of Action and Synthetic Lethality on Aml Cells When Combined with Venetoclax Dec 13
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML Dec 10 Aptose Biosciences Inc. has completed a Follow-on Equity Offering in the amount of $8 million. Nov 26
Aptose Biosciences Inc. Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-Based Triplet Therapy Nov 20
New major risk - Financial position Nov 17
Aptose Biosciences Receives Staff Determination Letter from Nasdaq Due to Failure to Meet the Terms of an Extension Oct 06
New major risk - Share price stability Aug 25
New major risk - Market cap size Aug 12
New major risk - Negative shareholders equity Aug 11 Aptose Biosciences Inc. has filed a Follow-on Equity Offering in the amount of $10 million. Aug 02
Aptose Announces Receipt of Deficiency Notice from Nasdaq Jul 20 Aptose Biosciences Inc. has completed a Follow-on Equity Offering. Jun 05
New major risk - Financial position Jun 05 Aptose Biosciences Inc. has filed a Follow-on Equity Offering in the amount of $4.43325 million. Jun 01
Aptose Biosciences Inc. to Report Q1, 2024 Results on May 14, 2024 May 08
Aptose Biosciences Receives a Letter from the Nasdaq Stock Market Stating the Company Was Not in Compliance with Nasdaq Listing Rule 5550(b)(1) Apr 07
Aptose Biosciences Inc., Annual General Meeting, May 28, 2024 Mar 20
Aptose Biosciences Inc. to Report Q4, 2023 Results on Mar 26, 2024 Mar 19
Aptose Biosciences Receives Deficiency Letter from The Nasdaq Stock Market LLC Mar 04 Aptose Biosciences Inc. announced that it has received $4 million in funding from Hanmi Pharm. Co., Ltd. Feb 01
New major risk - Shareholder dilution Jan 28 Aptose Biosciences Inc. has completed a Follow-on Equity Offering in the amount of $16.799998 million. Aptose Biosciences Inc. has filed a Follow-on Equity Offering in the amount of $16.799998 million. Jan 26
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting Dec 11
Aptose Biosciences Inc. Appoints Fletcher Payne as Chief Business Officer Dec 01
New major risk - Financial position Nov 11
Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting Nov 04
Aptose Biosciences Inc. Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib Oct 31
Aptose Biosciences Inc. to Report Q3, 2023 Results on Nov 09, 2023 Oct 27
Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th Oct 24
Independent Director recently bought €50k worth of stock Sep 26
Aptose Biosciences Inc. Provides A Recent Update from an Ongoing Aptivate Phase 1/2 Clinical Trial with the Company's Lead Agent, Tuspetinib Aug 25 Aptose Biosciences Inc. announced that it expects to receive CAD 7 million in funding from Hanmi Science Co., Ltd. Aug 11
Aptose Biosciences Inc. to Report Q2, 2023 Results on Aug 10, 2023 Jul 29
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance Jun 27
Aptose Biosciences Inc. Presents Highlights from Clinical Update Jun 13
Forecast to breakeven in 2025 Jun 07 Aptose Biosciences Inc. announced that it expects to receive CAD 25 million in funding May 26
Forecast to breakeven in 2025 May 10
Aptose Biosciences Inc. Announces the 120 Mg Monotherapy Dosing of Patients in the Aptivate Phase 1/2 Clinical Trial of Tuspetinib (Formerly Hm43239), an Oral, Mutation Agnostic Tyrosine Kinase Inhibitor (Tki) Being Developed for the Treatment of Patients with Relapsed or Refractory Acute Myeloid Leukemia Jan 31
Aptose Biosciences Inc. Updates Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations Dec 13
Aptose Biosciences Inc. Treats First Patient with Continuous Dosing of New “G3” Formulation of Luxeptinib Nov 15
Insufficient new directors Oct 31
Aptose Biosciences Inc. to Report Q3, 2022 Results on Nov 01, 2022 Oct 19
Aptose Biosciences Inc. Appoints Bernd R. Seizinger to the Board of Directors Sep 14
Aptose Biosciences Inc.’s New G3 Formulation of Luxeptinib Boosts Bioavailability Sep 13
Aptose Biosciences Receives a Deficiency Letter from the Nasdaq Listing Qualifications Department Regarding Minimum Bid Price Requirement Jul 23
Aptose Biosciences Inc. to Report Q2, 2022 Results on Aug 02, 2022 Jul 20 Aptose Appoints Fletcher Payne as Chief Financial Officer
Aptose Receives Fast Track Designation for Hm43239 in Relapsed/Refractory Aml Patients and Flt3 Mutation May 05
Insufficient new directors Apr 27
Aptose Biosciences Inc. to Report Q1, 2022 Results on May 09, 2022 Apr 26 Aptose Biosciences Inc. Announces Resignation of Dr. Jotin Marango as Chief Financial Officer
Aptose Biosciences Inc. Provides Update on APTO-253 Program Dec 21
Independent Director recently bought €281k worth of stock Dec 18
Aptose Biosciences Inc. Announces HM43239 Demonstrates Durable Clinical Benefit in Acute Myeloid Leukemia Dec 15
Insufficient new directors Sep 02
Independent Director recently sold €56k worth of stock Jun 24
Aptose Presents Highlights from EHA2021 Virtual Congress During Corporate Update Event Jun 13
Executive VP, Corporate Secretary, CFO & COO has left the company Mar 31
Aptose Biosciences Inc. to Report Q4, 2020 Results on Mar 23, 2021 Mar 03
New 90-day low: €3.22 Feb 28
New 90-day high: €5.55 Dec 01
Aptose Biosciences Inc. to Present CG-806 and APTO-253 Data At the 2020 Ash Annual Meeting Nov 06
New 90-day low: €3.96 Oct 29
Aptose Biosciences Inc. to Report Q3, 2020 Results on Nov 10, 2020 Oct 28
Aptose Initiates Dosing of CG-806 in Patients with Acute Myeloid Leukemia Oct 20
New 90-day low - €4.00 Aug 26
New 90-day low - €4.22 Jul 30
Aptose Biosciences Inc. to Report Q2, 2020 Results on Aug 04, 2020 Jul 22
Aptose Biosciences Inc. has completed a Follow-on Equity Offering in the amount of $55.125 million. Jul 18 Shareholder Returns LTI DE Biotechs DE Market 7D -8.8% 6.5% 1.3% 1Y -90.0% -1.9% 9.0%
See full shareholder returns
Return vs Market: LTI underperformed the German Market which returned 9% over the past year.
Price Volatility Is LTI's price volatile compared to industry and market? LTI volatility LTI Average Weekly Movement 29.5% Biotechs Industry Average Movement 7.3% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: LTI's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: LTI's weekly volatility has increased from 20% to 29% over the past year.
About the Company Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. The company’s clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin’s lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd.
Show more Aptose Biosciences Inc. Fundamentals Summary How do Aptose Biosciences's earnings and revenue compare to its market cap? LTI fundamental statistics Market cap €12.68m Earnings (TTM ) -€34.94m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) LTI income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$35.80m Earnings -US$35.80m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.60 Gross Margin 0.00% Net Profit Margin 0.00% Debt/Equity Ratio -109.5%
How did LTI perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/12 02:36 End of Day Share Price 2025/01/10 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Aptose Biosciences Inc. is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Dylan Dupuis B. Riley Securities, Inc. John Newman Canaccord Genuity Joseph Pantginis H.C. Wainwright & Co.
Show 7 more analysts 
